创模生物科技(北京)有限公司

CN / En

NEWS

Immunogenicity Detection Platform of InnoModels Biotechnology

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-28 16:44
  • Views:

(Summary description)In the field of biopharmaceuticals, the safety and efficacy of drugs are crucial aspects of the R&D process. Immunogenicity is one of the key indicators for assessing the potential risk of a drug, and the accuracy and reliability of its detection platform directly affects the process and results of new drug development. With its advanced immunogenicity testing platform, InnoModels Biotechnology (Beijing) Co., Ltd. provides strong technical support and guarantee for new drug R&D.

Immunogenicity Detection Platform of InnoModels Biotechnology

(Summary description)In the field of biopharmaceuticals, the safety and efficacy of drugs are crucial aspects of the R&D process. Immunogenicity is one of the key indicators for assessing the potential risk of a drug, and the accuracy and reliability of its detection platform directly affects the process and results of new drug development. With its advanced immunogenicity testing platform, InnoModels Biotechnology (Beijing) Co., Ltd. provides strong technical support and guarantee for new drug R&D.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-28 16:44
  • Views:
Information

In the field of biopharmaceuticals, the safety and efficacy of drugs are crucial aspects of the R&D process. Immunogenicity is one of the key indicators for assessing the potential risk of a drug, and the accuracy and reliability of its detection platform directly affects the process and results of new drug development. With its advanced immunogenicity testing platform, InnoModels Biotechnology (Beijing) Co., Ltd. provides strong technical support and guarantee for new drug R&D.
Platform background and strength:
Ltd. was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and the Institute of Immunology of Shanghai Jiaotong University. Relying on the stable domestic platforms of Humanized Immune System (HIS) and Human Tumor Xenograft (PDX), the company focuses on oncology and tumor immunopharmacodynamics CRO services, translational medicine research services, and individualized medicine. These platforms and services provide new-generation experimental animal models close to the clinic for new drug discovery companies, translational medicine researchers and tumor patients, and help the research and development of oncology and tumor immunotherapy.
Advantages of Immunogenicity Detection Platform:
●Advanced technology and equipment
InnoModels' immunogenicity testing platform adopts advanced testing technology and equipment to ensure the accuracy and reliability of the test results. The platform is capable of comprehensively evaluating the immunogenicity of drugs, including cellular immunity, humoral immunity, and hypersensitivity reactions, which meets the testing needs at different stages of new drug development.
●Professional Team and Services
The platform has an experienced and skilled team, who not only have a strong background in immunology, but also have rich experience in drug discovery and development. This team is able to provide customers with professional immunogenicity research services, from experimental design, sample processing to data analysis, to ensure the accuracy and reliability of test results in all aspects.
●Comprehensive Evaluation Capabilities
InnoModels' immunogenicity testing platform is capable of providing comprehensive immunogenicity assessment services. By detecting the effect of a drug on the immune system and assessing the type and degree of immune response it may trigger, it provides a scientific basis for new drug development. This comprehensive assessment capability helps to reduce the risk of new drugs in clinical trials and improve the success rate of R&D.

 


Practical application case:
In the process of new drug development, a new drug project requires a comprehensive assessment of its immunogenicity before entering clinical trials. Through InnoModels' immunogenicity testing platform, the researchers conducted an in-depth study on the immunogenicity of the new drug. Experimental results showed that the drug would not trigger serious immune reactions during the clinical trial, providing a strong guarantee for the smooth progress of the clinical trial. This successful case fully proves the accuracy and reliability of InnoModels' immunogenicity testing platform.
Future Prospects:
With the continuous development of the biopharmaceutical field, the importance of immunogenicity testing in new drug discovery and development is becoming more and more prominent. InnoModels Biotechnology will continue to devote itself to technological innovation and upgrading, and constantly improve the performance and service level of its immunogenicity testing platform. In the future, the platform will be applied in more fields, providing more comprehensive and accurate evaluation services for new drug development, and contributing more to the health of mankind.
In conclusion, with its advanced technology, professional team and comprehensive evaluation capability, the immunogenicity testing platform of InnoModels Biotechnology plays a crucial role in new drug development. It is believed that in the future development, the platform will continue to lead the industry's progress and bring more innovations and breakthroughs to the biomedical field.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司